Soluble PD-L1 correlates with melanoma outcomes

“Given that PD-L1 expression in most studies seems to be associated with response to anti-PD1, it’s a little bit curious that the soluble PD-L1 would give the opposite finding,” he said.

He added that it’s still unclear, but worth pursuing, whether measuring sPD-L1 levels can identify patients who may benefit from anti-PD1 monotherapy versus combinatorial strategies and agrees with the authors’ conclusion that larger studies are needed to establish whether sPD-L1 can be a prognostic or predictive biomarker.

The study was supported by grants from the National Institutes of Health, Mayo Clinic, and Fraternal Order of Eagles Cancer Research Fund. Dr. Dronca disclosed institution research funding from Merck Sharp & Dohme, and other financial relationship with Elsevier. Dr. McNeel disclosed leadership, stock ownership, and consulting with Madison Vaccines, and consulting and/or institutional research funding from Bristol-Myers Squibb, Dendreon, Janssen, Madison Vaccines, and Medivation.

op@frontlinemedcom.com

,